In a new commentary appearing in The Wall Street Journal, Precision Health Economics cofounders Dana Goldman and Darius Lakdawalla turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. In baseball, the salaries are high and the talent pool is deep. In pharma the debate remains: How much do we need to pay today to keep drug discovery alive tomorrow?

To read the complete commentary, please click here.